Why Supply Chain Separation Between Research and Clinical Operations Matters
One of the most important structural decisions for practices exploring retatrutide is whether and how to separate the supply chain for research activities from the supply chain for standard clinical care.
Why Supply Chain Separation Between Research and Clinical Operations Matters
One of the most important structural decisions for practices exploring retatrutide is whether and how to separate the supply chain for research activities from the supply chain for standard clinical care. This is not just an operational question — it is a compliance and liability question with direct implications for your practice's risk profile and valuation.
The Core Problem With Commingled Supply Chains
When a practice uses the same supply chain, the same storage systems, and the same dispensing processes for both approved compounded medications and investigational compounds like retatrutide, it creates several problems.
First, it makes it harder to demonstrate that the investigational compound was used only within a properly authorized research framework. Second, it creates documentation ambiguity that regulators and M&A buyers will scrutinize. Third, it increases the risk that an enforcement action related to the investigational compound will affect the practice's broader operations.
What Separation Looks Like in Practice
Structural separation does not necessarily require a separate physical facility, though that is the cleanest approach. At minimum, it means:
- Separate ordering and receiving processes for research compounds versus clinical compounds.
- Separate storage with distinct labeling and access controls.
- Separate dispensing records and patient files for research participants versus standard patients.
- Clear documentation of the legal authority under which each supply category is used.
The M&A Implication
Buyers conducting due diligence on a practice that has been involved with investigational compounds will look specifically at whether the practice maintained clear separation between research and clinical operations. A practice that can demonstrate clean separation is in a materially better position than one that cannot.
Key Takeaway
Supply chain separation between research and clinical operations is a structural protection that reduces regulatory risk, supports a defensible compliance position, and improves how your practice is evaluated in an M&A transaction.
Related reading: Building a Legally Defensible Position · IRB Enrollment for Practices · M&A Advisory
Disclaimer: This content is for educational and business strategy purposes only. It is not legal or medical advice.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
